Additionally, elevating the IGFBP2 expression could lead to attenuate sensitivity to MAPK signaling inhibitors, and thereby increasing BRAFV600E melanoma cell survival via triggering IGF-1R/AKT signaling pathway. Here, AKT1 is linked to melanoma.